MetaCap

Sionna Therapeutics Inc. (SION)

NASDAQ: SIONHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.83-0.145 (-4.88%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SION stock chart

Technical analysis

Key statistics

All statistics
Market cap
$127.79M
EPS (TTM)
-$2.43
52-week range
2.75 – 54.97
Day range
2.76 – 3.06
Volume / Avg
547.66K / 1.12M
Beta
—

52-week range

$2.75$54.97

SION stock today

Shares of Sionna Therapeutics (SION) finished lower on Nov 20 at $2.83, a drop of 4.88% or $0.145 per share, versus the S&P 500's 3.70% decline. Trading was light, with 547.66K shares changing hands, about 49% of the average daily volume. Shares are 94.9% below their 52-week high of $54.97, set on Aug 7, 2026 and 2.6% above the 52-week low of $2.75, near the bottom of the past year's range.

SION is down 93.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 93.5%. Sionna Therapeutics has posted a net loss over the last twelve months (EPS of -$2.43), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sionna Therapeutics

Company profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael Cloonan M.B.A.
Headquarters
Waltham, MA
Employees
59
IPO year
2025

Financial highlights

Full financials

Sionna Therapeutics reported a net loss of $75.3 million, compared with a loss of $61.7 million a year earlier. Diluted earnings per share came in at -$1.88.

Sionna Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue——
Growth——
Net income$-75.27M$-61.69M
EPS (diluted)$-1.88$-15.99

Analyst forecast

Forecast

Consensus (12 analysts)

hold

Avg. price target

$21.00+643.36%

  • Strong buy 0
  • Buy 2
  • Hold 10
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $63.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.72 vs $-0.62
Surprise
-16.13%

SION news

All SION news

Sionna Therapeutics peers

Health Care sector
SION peer companies
CompanyPrice% ChgMarket capCompare
MGNXMacroGenics Inc.1.96-1.01%$125.26Mvs SION
ZNTLZentalis Pharmaceuticals Inc.1.360.00%$133.64Mvs SION
MSLESatellos Bioscience Inc.5.68-2.07%$120.51Mvs SION
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs SION
ADAGAdagene Inc. ADR1.76-12.44%$118.17Mvs SION
OKUROnKure Therapeutics Inc. Class A2.70-2.17%$111.21Mvs SION
IMUXImmunic Inc.6.99-5.41%$111.01Mvs SION
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs SION

Indexes, lists and sector

Sionna Therapeutics stock FAQ

What is Sionna Therapeutics's stock price today?

SION last traded at $2.83 as of Nov 20, 4:00 PM EST, down 4.88% on the day. Prices are delayed at least 15 minutes.

Who is Sionna Therapeutics's CEO?

Mr. Michael Cloonan M.B.A. is the chief executive officer of Sionna Therapeutics Inc., which has about 59 employees.

What is the SION 52-week high?

The 52-week high for SION is $54.97 and the 52-week low is $2.75. The stock is currently 94.9% below its high.

Compare SION